Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Oral Nilotinib
The goal of this clinical research study is to learn if an experimental agent,
AMN107 (nilotinib), can help to control CML in chronic phase. The safety of
this experimental agent will also be studied.
Phase of Study:
Only at MDACC
Estimated Length of Stay in Houston:
Every 3-4 months for 1 year, then every 6-12 months.
All therapy is self-administered.
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List